BIAFW bioAffinity Technologies, Inc. - Warrant
0.2615USD+10.34%Mkt Cap: —P/E: —6d ago
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United Sta…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)5.90M USD
Gross Profit1.88M USD
Net Income (TTM)-14.91M USD
Revenue/Share23.20 USD
Last Price0.2615 USD
Fiscal Year End—
MR Quarter—
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.07
EPS (TTM)—
EPS (Forward)—
52W Range
0.050137% of range0.6200
52W High0.6200 USD
52W Low0.0501 USD
Profitability
Gross Margin30.80%
Oper. Margin-220.77%
EBITDA Margin-202.82%
Profit Margin-244.10%
ROE-204.87%
ROA-136.03%
Growth
Revenue Growth19.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.33M USD
CapEx (TTM)60.57K USD
FCF Margin-117.09%
FCF Yield—
Net Debt-994.71K USD
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.16
Current Ratio1.44
Quick Ratio1.24
Book Value/Sh8.34 USD
Cash/Share4.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float532.26K
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta-1.25
S&P 52W Chg15.78%
Avg Vol (30d)4.35K
Avg Vol (10d)—
Technical Indicators
RSI (14)64.2
MACD0.0479
MACD Signal0.0184
MACD Hist.+0.0295
BB Upper0.5015 USD
BB Middle0.2037 USD
BB Lower-0.0940 USD
BB Width292.32%
ATR (14)0.0962 USD
Vol Ratio (20d)0.19x